Navigation Links
DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
Date:2/11/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 11, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the third closing in a private placement consisting of approximately 1.2 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.0 million. The total amount raised in the private placement is $7.9 million.

Charles Vista, LLC acted as the company's placement agent in the unit offering. Each unit consists of one share of common stock and one common stock purchase warrant.  The maximum offering in the Private Placement consisted of 9,375,000 units for gross proceeds of $7.5 million.  In addition, the placement agent has been granted an over-allotment option of up to 3,125,000 units to cover over-subscriptions for additional gross proceeds of up to $2.5 million.  The over-allotment option is being exercised in part in connection with today's closing.

About DelMar Pharma

Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com;   
or contact Jeffrey A. Bacha , President & CEO  (604) 629-5989


'/>"/>
SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 ... Piramal Enterprises Limited, gibt die Ernennung von ... PPS bietet seinen globalen Pharmazeutikkunden eine einmalige ... eine wichtige Rolle für das erfolgreiche Wachstum ... kaufmännischer Leiter wird Herr Needleman dafür verantwortlich ...
(Date:3/23/2017)... March 23, 2017 Pre-market today, Stock-Callers.com ... PLC (NYSE: AGN), Horizon Pharma PLC (NASDAQ: HZNP), and Evoke ... stocks are part of the Healthcare sector, which was slightly ... 2017, with the NYSE Health Care Index adding about 0.1% ... S&P 500 also were up nearly 0.1% as a group. ...
(Date:3/23/2017)... 23, 2017 AbbVie, a global biopharmaceutical company, ... Julianne Hough is helping to raise awareness ... Know about ME in EndoMEtriosis . "   The ... to learn about and understand endometriosis, a disease affecting ... to address their symptoms with a healthcare professional.  Despite ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare ... Assurance, at HCCA’s 21st annual Compliance Institute on March 26-28 in National Harbor, ... for all medical chart types with a comprehensive set of features including built-in ...
(Date:3/23/2017)... ... ... Woman Be Ye Healed-Passing On A Legacy”: a call to heal the wounded Church. ... author, Desiree M Webb, a registered nurse, minister of music, speaker, songwriter, recording artist, ... husband, Paul, for over twenty-nine years. Desiree enjoys writing, beach trips, ministering in ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... the existence of God. “A Respectful Response To Atheist Manifesto” is the creation ... married to his wife, Nancy, for sixty years. He holds graduate degrees from ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex Biosciences, provider ... protein expression in circulating tumor cells using microfluidic western blotting” in Nature Communications ... Vortex technology to capture CTCs and a microfluidic single-CTC resolution Western ...
(Date:3/22/2017)... ... March 23, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had won the ‘Clinical ... at the Suntec Singapore International Exhibition & Convention Centre, Singapore. The award was ...
Breaking Medicine News(10 mins):